DEA Revokes Arizona Nurse's License Over Drug Violations
Published Date: 4/22/2025
Notice
Summary
Svetlana Burtman, a nurse practitioner in Arizona, had her DEA registration suspended and is facing revocation because she broke important rules about handling controlled substances. The government found she gave out drugs from an unregistered location and didn’t keep proper records, which could risk public safety. This decision means she can’t legally dispense these drugs anymore, and her new clinic’s registration was also denied.
Analyzed Economic Effects
5 provisions identified: 0 benefits, 5 costs, 0 mixed.
DEA Registration Revoked for Practitioner
The Drug Enforcement Administration agreed to revoke Svetlana Burtman’s DEA Certificate of Registration No. MB2645767 and suspended that registration after an Order to Show Cause on December 28, 2023. The Decision and Order (published April 22, 2025) means she can no longer legally dispense or administer controlled substances under that registration.
New Clinic Registration Denied
The DEA denied Respondent’s application for a separate registration for her Green Valley Clinic (application No. W23106194M), and the Agency found she dispensed controlled substances at that unregistered location. The Agency’s findings note she dispensed at Green Valley after July 19, 2023 and that the GVC application was not approved.
Separate Registration Required per Location
The Agency reaffirmed that each principal place of business where controlled substances are dispensed requires a separate DEA registration under 21 CFR 1301.12(a). The Decision points to the Green Valley Clinic as an unregistered location where dispensing occurred, citing dispensing logs and admissions.
Strict Recordkeeping and Dispensing Log Rules Enforced
The Agency found Respondent failed to maintain complete, readily retrievable records of controlled substances received (citing 21 U.S.C. 827 and 21 CFR 1304.04/1304.21) and failed to keep required dispensing logs (21 CFR 1304.22(c)). The missing Tucson purchase invoice records and incomplete dispensing logs were relied on in the Agency’s decision.
Must Accept Responsibility to Retain Registration
The Decision reiterates that a registrant seeking to retain or regain a DEA registration must unequivocally accept responsibility for misconduct and demonstrate they will not reoffend. The Agency found Respondent minimized her unlawful conduct and did not meet that standard.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-06879 — National Center for Advancing Translational Sciences; Notice of Closed Meeting
The National Center for Advancing Translational Sciences is holding a private meeting on May 14-15, 2025, to review secret contract proposals about developing new drug products. This meeting affects companies and researchers involved in drug development and keeps sensitive info safe. No public money changes are announced, but the decisions could impact future drug research funding.
Next: 2025-06883 — Information Collection Being Reviewed by the Federal Communications Commission Under Delegated Authority
The FCC is asking the public and other agencies to help review and improve how it collects information, aiming to cut down on paperwork and make things easier for everyone—especially small businesses. They want to know if the info they ask for is really needed, clear, and not too much of a hassle. This is a chance to share ideas before any changes happen, so keep an eye out and speak up!